摘要
目的:观察芪苈强心胶囊联合沙库巴曲缬沙坦治疗射血分数保留的心力衰竭(HFPEF)患者的效果。方法:选取2020年7月至2021年5月该院收治的120例HFPEF患者进行前瞻性研究,采用随机数表法将其分为对照组与观察组各60例。对照组采用沙库巴曲缬沙坦治疗,观察组在对照组基础上联合芪苈强心胶囊治疗,比较两组治疗前后心功能指标[左心室射血分数(LVEF)、高峰射血率(PER)、每搏输出量(SV)]水平、疾病相关指标[脑钠肽(BNP)、肌钙蛋白T(cTnT)、肌酸激酶同工酶(CK-MB)]水平、6分钟步行试验(6MWT)距离和不良反应发生率。结果:治疗后,两组LVEF、PER、SV水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组BNP、cTnT、CK-MB水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组6MWT距离均长于治疗前,且观察组长于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:芪苈强心胶囊联合沙库巴曲缬沙坦治疗HFPEF患者可提高心功能指标水平,延长6MWT距离,降低疾病相关指标水平,其效果优于单纯沙库巴曲缬沙坦治疗。
Objective:To observe effects of Qiliqiangxin capsules combined with Sacubitril/Valsartan in treatment of patients with heart failure with preserved ejection fraction(HFPEF).Methods:A prospective study was conducted on 120 patients with HFPEF admitted to this hospital from July 2020 to May 2021.They were divided into control group and observation group by using the random number table method,60 cases in each group.The control group was treated with Sacubitril/Valsartan,while the observation group was treated with Qiliqiangxin capsules on the basis of that of the control group.The levels of cardiac function indexes[left ventricular ejection fraction(LVEF),peak ejection rate(PER),stroke volume(SV)]and the disease-related indexes[brain natriuretic peptide(BNP),troponin T(cTnT),creatine kinase isoenzyme(CK-MB)],6-minute walking test(6MWT)distance,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:After the treatment,the levels of LVEF,PER and SV in the two groups were higher than those before the treatment,those in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of BNP,cTnT and CK-MB in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The 6MWT distance of the two groups was longer than that before the treatment,that of the observation group was longer than that of the control group,and the difference was statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Qiliqiangxin capsules combined with Sacubitril/Valsartan in the treatment of the HFPEF patients can improve the levels of cardiac function indexes,short the 6MWT distance,and reduce the levels of disease-related indexes.Moreover,it is superior to single Sacubitril/Valsartan treatment.
作者
李晨
陈统
马金霞
LI Chen;CHEN Tong;MA Jinxia(Nanyang First People’s Hospital,Nanyang 473000 Henan,China)
出处
《中国民康医学》
2023年第18期105-108,共4页
Medical Journal of Chinese People’s Health
基金
南阳市2020年市级科技计划项目(KJGG124)。
关键词
沙库巴曲缬沙坦
芪苈强心胶囊
射血分数保留
心力衰竭
心功能
不良反应
Sacubitril/Valsartan
Qiliqiangxin capsules
Preserved ejection fraction
Heart failure
Cardiac function
Adverse reaction
作者简介
李晨(1993.09-),男,汉族,河南方城人,本科,住院医师,研究方向为心血管临床;通信作者:马金霞(1971.08-),女,回族,河南南阳人,本科,主任医师,研究方向为心力衰竭。E-mail:69379961@qq.com。
